- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Interventions
- Boostrix
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 19 Years to 30 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,281
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autism Spectrum Disorder
- Interventions
- LCPUFA Oil Supplement, Canola Oil Placebo
- Drug · Dietary Supplement
- Lead sponsor
- Sarah Keim
- Other
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Leukemia
- Interventions
- recombinant interferon alfa, amifostine trihydrate, bromodeoxyuridine, cytarabine, idarubicin, idoxuridine, isotretinoin, mitoxantrone hydrochloride
- Biological · Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 0 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 1999
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Kankakee, Illinois
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose), Other: Placebo
- Drug · Other
- Lead sponsor
- Nitto Denko Corporation
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Los Angeles, California • Northridge, California + 18 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- therapeutic allogeneic lymphocytes
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Milwaukee, Wisconsin
- Conditions
- Neuroblastoma
- Interventions
- Not listed
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 31 Days to 99 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2099
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- GM-CSF
- Biological
- Lead sponsor
- Edward Nelson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
- Interventions
- APL-2
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 17
- States / cities
- Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more
- Conditions
- Circadian Misalignment, Sex Differences
- Interventions
- Day shift, Night shift
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD
- Interventions
- Corus CAD (ASGES)
- Diagnostic Test
- Lead sponsor
- CardioDx
- Industry
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 4,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 10
- States / cities
- Anchorage, Alaska • Beverly Hills, California • La Jolla, California + 7 more
- Conditions
- Avian Influenza, H1N1 Influenza, Influenza
- Interventions
- AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Ventral Incisional Hernia
- Interventions
- Gentrix™ Surgical Matrix (Treatment), Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)
- Device
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Tampa, Florida
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes
- Interventions
- thalidomide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Arthritis, Psoriatic
- Interventions
- Icotrokinra, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 25
- States / cities
- Glendale, Arizona • Mesa, Arizona • Jonesboro, Arkansas + 22 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 103
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Placebo matching BMS-945429, BMS-945429
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more
- Conditions
- Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
- Interventions
- Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
- Drug · Procedure
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 12
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Ankle Osteoarthritis
- Interventions
- Axolotl Ambient, "Drug/Placebo: 0.9% Normal Saline"
- Biological · Drug
- Lead sponsor
- Axolotl Biologix
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Boise, Idaho • Shreveport, Louisiana • Charlotte, North Carolina
- Conditions
- Herpes Zoster
- Interventions
- Herpes Zoster vaccine GSK 1437173A, Boostrix
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 935 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • San Diego, California • Stockbridge, Georgia + 9 more
- Conditions
- Vision Disorders
- Interventions
- Aerobic exercise, Balance exercise
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
- Interventions
- Cisplatin, Docetaxel, Bevacizumab, Erlotinib, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- deuterated-Bisphenol A (d-BPA)
- Other
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 25 Years to 45 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Full Thickness Rotator Cuff Tear
- Interventions
- Mesenchymal stem cell augmentation in rotator cuff repair, Standard arthroscopic rotator cuff repair
- Biological · Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois